Search

Your search keyword '"Perrier, Hervé"' showing total 35 results
Start Over Author "Perrier, Hervé" Language english
35 results on '"Perrier, Hervé"'

1. Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort

Author

Tougeron, David, Bibeau, Frederic, Chibaudel, Benoist, Kim, Stefano, Nguyen, Thierry, Phelip, Jean-Marc, Mille, Dominique, Bouattour, Mohamed, Tavan, David, Rinaldi, Yves, Lecomte, Thierry, Perrier, Hervé, Spaeth, Dominique, Caroli Bosc, François-Xavier, Metges, Jean-Philippe, Ferec, Marc, Hautefeuille, Vincent, Deslandres-Cruchant, Marion, Danion, Jerome, Hammel, Pascal, Lewin, Maïté, Tasu, Jean-Pierre, Angelergues, Antoine, DiFiore, Frederic, Evrard, Serge, Mansar, Racha, Caillou, Hugo, Geffriaud-Ricouard, Christine, and Adam, René

Published
2024
Full Text
View/download PDF

2. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial

Author

Botsen, Damien, Chabaud, Sylvie, Perrier, Hervé, Ammarguellat, Hanifa, Jestin-Le-Tallec, Véronique, Olesinski, Jonathan, Toullec, Clémence, Aparicio, Thomas, Ben Abdelghani, Meher, Borg, Christophe, Bouche, Olivier, Coutzac, Clélia, Devaud, Hervé, Di Fiore, Frédéric, Dubreuil, Olivier, Evesque, Ludovic, Huguenin, Bruno, Muller, Marie, Poureau, Pierre-Guillaume, Oularue, Emilie, Tougeron, David, Zaanan, Aziz, Ammari, Samy, De Sousa Carvalho, Nicolas, Decazes, Pierre, and De La Fouchardiere, Christelle

Published
2024
Full Text
View/download PDF

4. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

Author

Turpin, Anthony, de Baere, Thierry, Heurgué, Alexandra, Le Malicot, Karine, Ollivier-Hourmand, Isabelle, Lecomte, Thierry, Perrier, Hervé, Vergniol, Julien, Sefrioui, David, Rinaldi, Yves, Edeline, Julien, Jouve, Jean-Louis, Silvain, Christine, Becouarn, Yves, Dauvois, Barbara, Baconnier, Mathieu, Debette-Gratien, Maryline, Deplanque, Gael, Dharancy, Sébastien, Lepage, Côme, and Hebbar, Mohamed

Published
2021
Full Text
View/download PDF

5. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Author

Taïeb, Julien, André, Thierry, El Hajbi, Farid, Barbier, Emilie, Toullec, Clémence, Kim, Stefano, Bouche, Olivier, Di Fiore, Frederic, Chauvenet, Marion, Perrier, Hervé, Evesque, Ludovic, Laurent-Puig, Pierre, Emile, Jean-François, Bez, Jérémie, Lepage, Côme, and Tougeron, David

Published
2021
Full Text
View/download PDF

6. Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study.

Author

Adhoute, Xavier, Gonzalez, Alexia, Levi-strauss, Thomas, Mineur, Laurent, Pénaranda, Guillaume, Sellier, Floriane, Toullec, Clémence, Pietri, Olivia, Castellani, Paul, Tran, Albert, Perrier, Hervé, Bourliere, Marc, and Anty, Rodolphe

Published
2024
Full Text
View/download PDF

7. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Moulin, Solenne, Leleu, Olivier, Leparree, Sylvie, Goasdoue, Henri, Piprot, Christine, Tourneur, Gerald, Bayart, Vincent, Lignier, Delphine, Lachaier, Emma, Khamari, Marwa, Coutte, Alexandre, Siembida, Nicolas, Houessinon, Aline, Regimbeau, Jean Marc, Chauffert, Bruno, Moreira, Aurélie, Hautefeuille, Vincent, Hee, Christine, Boone, Mathieu, Bihan, Céline, Chive, Emilie, Poulet-Potriquier, Stéphane, Fahem, Rachida, Luet, Dominique, Roquin, Guillaume, Vitellius, Carole, Cornet-Trichereau, Nathanaëlle, Caroli-Bosc, François-Xavier, Thirot-Bidault, Anne, Ropert, Stanislas, Gachet - Masson, Julie, Dehais, Mélanie, L'helgoualc'h, Gwen-Ael, Ali-Mahamadou, Ibrahim, Talfi, Safia, Belmont, Laure, Kilendo, Dieudonné, Benrezzak, Nasro, Dubief, Emeline, Conroy, Guillaume, Delique, Laurence, Basso, Maud, Pons, Isabelle, Salignon, Karine, Villing, Anne-Laure, Mougenot, Emmanuelle, Porebski, Cassandra, Guiatni, Asma, Cloarec, Nicolas, Mineur, Laurent, Bouchaud, Marie, David, Céleste, Peytier, Annie, Greletty, Thomas, Audemar, Franck, Vignes, Emanuelle, Minne, Floriane, Goldzak, Guillaume, Huysman, Fabienne, Hocine, Fayçal, Lakkis, Zaher, Mansi, Laura, Meynard, Guillaume, Almotlak, Hamadi, Klajer, Elodie, Sun, Xu-Shan, Wasselin, Julie, Catala, Pascale, Mazuy, Claire, Vandamme, Hélène, Prevost, Jean-Briac, Fadin, Aurélie, Basson, Laurent, Huguet, Jean-Baptiste, Dos Santos, Emmanuelle, Jany, Bérangère, Saad, Alain, Goutorbe, Frédéric, Oziol, Eric, Ramdani, Mohamed, Kadiri, Ouafae, Garbay, Delphine, Huet, Clotilde, Giroux Leprieur, Etienne, Teng, Wen, Monvoisin, Justine, Arnaud Coffin, Patrick, Roux, Sylvie, Orfeuvre, Hubert, Chagros, Mélanie, Pillon, Didier, Rassoul, Agathe, Poureau, Pierre Guillaume, Novello, Cécile, Ducray, François, Trouba, Cécile, Bastit, Vianney, Babin, Emmanuel, Thariat, Juliette, Leon, Vincent, Courtecuisse, Anne-Catherine, Vambre, Julie, Tack, Vincent, Desauw, Christophe, Meniai, Fatima, Peres, Christina, Esparcieux, Aurélie, Perrier, Hervé, Doux, Nathalie, Kaphan, Régis, Roques, Bertrand, Rebischung, Christine, Mille, Dominique, Fernandes, Gaëlle, Abdelli, Naceur, Jousset, Natacha, Combe, Pierre, Jonveaux, Eric, Dumont, Patrick, Kanaan, Marc, Berthelot Gras, Corinne, Panis, Valérie, Kaluzinski, Laure, Venant-Valery, Marjolène, Lam, You-Heng, Vallee, Laura, Riviere, Frédéric, Durand, Muriel, Benghadid, Dihya, Villeneuve, Emilie, Hentic Dhome, Olivia, Laurent, Lucie, Bounouar, Zedjiga, De Mestier, Louis, Dubois, Jacqueline, Eyriey, Magali, Moreau, Lionel, Ahle, Guido, Baihas, Dib, Aldabbagh, Kaïs, Degriffolet, Dominique, Sebbagh, Virginie, Seghezzi, Jean-Christophe, Lozach-Brugirard, Marion, Mandrou, Julie, Mavier, Loubna, Hennetier, Florence, Wagner, Jean-Philippe, Carola, Elisabeth, Chandirakumaran, Karthiga, Loutski, Sandrine, Cojean-Zelek, Isabelle, Bouras, Amina, Lacour, Sandrine, Froura, Fahem, Ben Nadji, Hadjer, Cattelain, Sophie, Darloy, Franck, Jolimoy Boilleau, Geneviève, Maissiat, Cyrielle, Darut-Jouve, Ariane, Lorgis, Véronique, Charifi-Alaoui, Ikram, Ghiringhelli, François, Drouillard, Antoine, Chaix, Marie, Manfredi, Sylvain, Lepage, Côme, Gagnaire, Alice, Latournerie, Marianne, jourdan, Sofia, Perrot, Nora, folia, Mireille, Minello, Anne, Jouve, Jean-Louis, Fery, Marielle, Landau, Alain, Evrard, Diane, Valenza, Bruno, Paitel, Jean-François, Chablais, Laetitia, Kreitmann, Thomas, Lancry-Lecomte, Laurence, Monard, Adrien, Faugeras, Eve, Boucheret, Paul, Glommeau, Cécile, Tchikladze, Christine, Garnier Tixidre, Claire, Long, Jérôme, Zaidi, Manel, Delabarre, Véronique, Meyzenc, Juliette, Ferrand, Loïc, Moro-Sibilot, Denis, Bouheret, Paul, Leyronnas, Cécile, Herve, Camille, Thoor, Audrey, Jacquet, Emanuelle, Roth, Gaël, Madapathage-Senanyake, Videsheka, Chupeau, Peggy, Bieber, Elsa, Rosso, Maud, Lepage, Isabelle, Priou, Frank, Laly, Margot, Aprelon, Sylvie, Sobolak, Natacha, Homokos, Helen, Pointreau, Yoann, Watelle, Fabienne, Pham-Becker, Alice, Lauridant, Géraldine, Turpin, Anthony, Dujardin, Charlotte, Lenglin, Etienne, Nienguet Tsota, Aimée, Dominguez, Sophie, Forestier, Alexandra, Nouvel, Franck, Lerooy, Justine, Ratajczak, Céline, Romano, Olivier, Brzyski, Dorothéee, Barriere, Aurélien, Genet, Dominique, Tisse, Julien, Zasadny, Xavier, Grelet, Adeline, Hennion-Imbault, Amélie, Haustraete, Eglantine, Louafi, Samy, Awad, Manal, Zekri, Younes, Cheneau, Caroline, Leissen, Nolwen, Egreteau, Joëlle, Breant, Alexandra, Sarabi, Matthieu, Labonne, Stéphanie, Forestier, Julien, Leclercq, Céline, Prunier-Bossion, Florence, Ray Coquard, Isabelle, Guillet, Marielle, Theillaumas, Aurélie, Prome, Emilie, Walter, Thomas, Philouze, Pierre, Lawo, Melody, De Talhouet, Solène, Beuvelot, Johanne, Molin, Yann, Bellecoste Martin, Marie, Saussereau, Maud, Agnelli, Lauren, Fakhry, Nicolas, Laplace, Christophe, Norguet Monnereau, Emmanuelle, Boucard, Céline, Djenad, Kahina, Fontaine, Catherine, Seitz, Jean-François, Dahan, Laétitia, Sigrand, Julie, Duluc, Muriel, Locher, Christophe, Fleury, Marjory, Brou Marie, Ange, Berkane, Ramdane, Poupblanc, Séverine, Auby, Dominique, Petran, Daniela, Texereau, Patrick, Guerineau, Elodie, Andre, Morgan, Mahjoubi, Linda, Sarrazin, Fanny, Jeanson, Sonia, Gschwend, Anthony, Birr, Virginie, Debieuvre, Didier, Fore, Mathieu, Noirclerc, Monique, Dahou, Sihem, Spaeth, Dominique, Lambotin, Mélanie, Lelu, Thomas, Linot, Benjamin, Hugon, Nathalie, Rousseau, Dominique, Castanie, Hélène, Lenne, Carole, Lortholary, Alain, Cessot, Anatole, Merzoug, Messaouda, Naudin, Cécile, Vannetzel, Jean-Michel, Aziz, Ghina, Hadj Arab, Yacine, Pernes, Stéphanie, Roche-Lachaise, Isabelle, Fiteni, Frédéric, Yahiaoui, Hadjer, Marel Lopez, Gwendoline, Oddoz, Jeanne, Peira, Fabienne, Michel, Olivier, Meunier, Jérôme, Ouahrani, Brahim, Roger, Antoine, Branco, Sonia, Nguyen, Van, Gisselbrecht, Mathilde, Hammad, Ghania, Mordant, Pierre, Stroksztejn, Magda, Pocard, Marc, Nlo Meyengue, Luc, Aparicio, Thomas, Sacco, Emmanuelle, Simon Anne, Sophie, Fabre-Guillevin, Elizabeth, Wislez, Marie, Slim, Marine, Zaanan, Aziz, Cadranel, Jacques, Pluvy, Johan, Ursu, Rénata, Geraldo, Amyrath, Lihi, Rime, Vo, Maryline, Brouk, Zohra, Colle, Raphaël, Bennamoun, Mostefa, Lacan, Fabrice, Louvet, Christophe, Mebarki, Soraya, Veyri, Marianne, Paillaud, Elena, Lucas, Christelle, Dubreuil, Olivier, Lyamani, Jamila, Idbaih, Ahmed, Agguini, Hanane, Soularue, Emilie, Canellas, Anthony, Zalcman, Gérard, Jourdaine, Clément, Verillaud, Benjamin, Herzine, Hakima, Raymond, Eric, Mathiot, Nathalie, Palmieri, Lola Jade, Epanya, Christian, Taieb, Julien, Bertrand, Eliane, Goujon, Gaël, Namour, Céline, Gazeau, Benoit, Zafirova, Biljana, Mirghani, Haitham, Belin, Catherine, Belkhir, Kahina, Gharib, Myriam, Vozy, Aurore, Amrane, Karim, Spano, Jean-Philippe, Wassermann, Johanna, Feuvret, Loic, Bachet, Jean-Baptiste, Philonenko, Sara, Guillot, Laetitia, Zabbe, Marion, Gibiat, Stéphanie, Baylot, Camille, Jouinot, Aude, Leduc, Nicolas, Vieillot, Sabine, James, Laurie, Ducerf, Camille, Blanc, Jean-Frédéric, Falandry Leger, Claire, Wautot, Virginie, Chauvenet, Marion, Vincent, Aude, Tougeron, David, Goulvent, Sandrine, Suc, Etienne, Laurenty, Anne-Pascale, Marquis, Eric, Bonnaire, Margaux, Dewolf, Maxime, Brenet, Esteban, Billard, Delphine, Litre, Claude-Fabien, Dumazet, Antoine, Botsen, Damien, Vazel, Marion, Carlier, Claire, Bonnerave, David, Marchand-Crety, Charles, Bouche, Olivier, Fosse, Patricia, Sefrioui, David, Michel, Pierre, Watson, Sarah, Neuzillet, Cindy, Torche, Fatah, Muron, Thierry, Natur, Stéphane, Desgrippes, Romain, Bihel, Véronique, Ferrand, François-Régis, Leiterer, Caroline, Lavole, Julie, Moquet, Claire, Pressoir, Nathalie, Dziukala, Catherine, Ligeza Poisson, Catherine, Naji, Abdelhalim, Williet, Nicolas, Phelip, Jean-Marc, Di Palma, Fabrice, Kherrour Mehdi, Amina, Langrand-Escure, Julien, Fournel, Pierre, Pigne, Grégoire, Saban-Roche, Léa, Magne, Nicolas, Vassal, Cécile, Jacquin, Jean-Philippe, Ramirez, Carole, Vallard, Alexis, Collard, Olivier, Rivoirard, Romain, Graber, Ivan, Trager Maury, Stéphanie, Duboisset, Elodie, Ayllon Ugarte, Jorge, Rami, Dalilia, Saler, Christine, Reinbolt, Manon, Le Fevre, Clara, Ben Abdelghani, Meher, Dourthe, Louis-Marie, Perruisseau-Carrier, Joffrey, Nguimpi-Tambou, Marlène, Barret, Flavie, Di Stefano Anna, Luisa, Balthazard, Annie, Mabro, May, Vassord-Dang, Camille, Le Marchand, Mathilde, Vergniol, Julien, Pripon, Iulia, Daemaegdt, Axelle, Latry, Vanessa, Larrieu, Muna, Landry, Gaëlle, Touihri Maximin, Laetitia, Del Piano, Francesco, Barlet, Agnès, Vernisse, Mylène, Lafond, Sophie, Genin, Charline, Sibertin-Blanc, Camille, Chabrillac, Emilien, Gregoire, Caroline, Vergez, Sébastien, Panouille, Quentin, Guimbaud, Rosine, Richa, Floriane, Lebellec, Loïc, Gounin, Sophie, Buiret, Guillaume, Baudin, Marine, Hamon, Hervé, Deshorgue, Anne-Claire, Barrascout, Eduardo, Legrand, Stéphanie, Houlze, Morgane, Cambula, Linda, Lopez, Anthony, Fouquet, Guillaume, Touabi, Kahina, GermaIn, Adeline, Godbert, Benoit, Voivret, Florence, Perrin, Julie, Da Silva, Rosa, Bernichon, Emilie, Lièvre, Astrid, Ray-Coquard, Isabelle, Le Malicot, Karine, Paoletti, Xavier, Bouché, Olivier, Aldabbagh, Kais, Colle, Raphael, Hardy-Bessard, Anne-Claire, Colomba, Emeline, Bourhis, Jean, Gorphe, Philippe, Ursu, Renata, and Di Stefano, Anna Luisa

Published
2020
Full Text
View/download PDF

9. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial

Author

Malka, David, François, Eric, Penault-Llorca, Frédérique, Castan, Florence, Bouché, Olivier, Bennouna, Jaafar, Ghiringhelli, François, de la Fouchardière, Christelle, Borg, Christophe, Samalin, Emmanuelle, Bachet, Jean-Baptiste, Raoul, Jean-Luc, Miglianico, Laurent, Bengrine-Lefèvre, Leila, Dahan, Laetitia, Lecaille, Cédric, Aparicio, Thomas, Stanbury, Trevor, Perrier, Hervé, Cayre, Anne, Laurent-Puig, Pierre, Gourgou, Sophie, Emile, Jean-François, and Taïeb, Julien

Published
2019
Full Text
View/download PDF

10. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

12. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

Author

De La Fouchardière, Christelle, Malka, David, Cropet, Claire, Chabaud, Sylvie, Raimbourg, Judith, Botsen, Damien, Launay, Simon, Evesque, Ludovic, Vienot, Angélique, Perrier, Hervé, Jary, Marine, Rinaldi, Yves, Coutzac, Clélia, Bachet, Jean Baptiste, Neuzillet, Cindy, Williet, Nicolas, Desgrippes, Romain, Grainville, Thomas, Aparicio, Thomas, and Peytier, Annie

Published
2024
Full Text
View/download PDF

14. Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.

Author

Taïeb, Julien, Bouche, Olivier, André, Thierry, Le Malicot, Karine, Laurent-Puig, Pierre, Bez, Jérémie, Toullec, Clémence, Borg, Christophe, Randrian, Violaine, Evesque, Ludovic, Corbinais, Stéphane, Perrier, Hervé, Buecher, Bruno, Di Fiore, Frederic, Gallois, Claire, Emile, Jean Francois, Lepage, Côme, Elhajbi, Farid, and Tougeron, David

Published
2023
Full Text
View/download PDF

15. Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Author

Gronnier, Caroline, Mariette, Christophe, Lepage, Come, Monterymard, Carole, Jary, Marine, Ferru, Aurélie, Baconnier, Mathieu, Adhoute, Xavier, Tavan, David, Perrier, Hervé, Guerin-Meyer, Véronique, Lecaille, Cédric, Bonichon-Lamichhane, Nathalie, Pillon, Didier, Cojocarasu, Oana, Egreteau, Joëlle, D'journo, Xavier Benoit, Dahan, Laétitia, Locher, Christophe, and Texereau, Patrick

Subjects
THERAPEUTIC use of monoclonal antibodies, THERAPEUTIC use of antineoplastic agents, ADENOCARCINOMA, PERIOPERATIVE care, DRUG efficacy, CONFIDENCE intervals, CANCER chemotherapy, FLUOROURACIL, TREATMENT effectiveness, CISPLATIN, RESEARCH funding, COMPUTED tomography, PROGRESSION-free survival, ESOPHAGEAL tumors, PATIENT safety, OVERALL survival
Abstract

Simple Summary: The treatment of resectable gastric and gastroesophageal junction adenocarcinomas is enhanced by a strategy of perioperative chemotherapy (CT) when compared with surgery alone. But, there is still a need for new approaches to further improve outcomes in patients treated with perioperative CT. Cetuximab, a human–murine chimeric monoclonal antibody binds with a high affinity to the EGFR binding site, and has shown activity against a variety of tumors, including G/GEJ adenocarcinomas. This study aimed to evaluate the efficacy and safety of perioperative cetuximab combined with 5-fluorouracil and cisplatin for the treatment of gastric and esophageal adenocarcinoma. The results of this phase two study showed safety but lack of efficacy regarding objective tumor response and absence of major toxicity. Purpose: While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the efficacy and safety of perioperative cetuximab combined with 5-fluorouracil and cisplatin. Patients and Methods: Patients received six cycles of cetuximab, cisplatin, and simplified LV5FU2 before and after surgery. The primary objective was a combined evaluation of the tumor objective response (TOR), assessed by computed tomography, and the absence of major toxicities resulting in discontinuation of neoadjuvant chemotherapy (NCT) (45% and 90%, respectively). Results: From 2011 to 2013, 65 patients were enrolled. From 64 patients evaluable for the primary endpoint, 19 (29.7%) had a morphological TOR and 61 (95.3%) did not stop NCT prematurely due to major toxicity. Sixty patients (92.3%) underwent resection. Sixteen patients (/56 available, 28.5%) had histological responses (Mandard tumor regression grade ≤3). After a median follow-up of 44.5 months, median disease-free and overall survival were 24.4 [95% CI: 16.4–39.4] and 40.3 months [95% CI: 27.5–NA], respectively. Conclusion: Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.

Author

Phelip, Jean Marc, Desrame, Jérôme, Edeline, Julien, Barbier, Emilie, Terrebonne, Eric, Michel, Pierre, Perrier, Hervé, Dahan, Laetitia, Bourgeois, Vincent, Akouz, Faiza Khemissa, Soularue, Emilie, Ly, Valérie Lebrun, Molin, Yann, Lecomte, Thierry, Ghiringhelli, François, Coriat, Romain, Louafi, Samy, Neuzillet, Cindy, Manfredi, Sylvain, and Malka, David

Published
2022
Full Text
View/download PDF

18. Saliva Quantification of SARS-CoV-2 in Real-Time PCR From Asymptomatic or Mild COVID-19 Adults.

Author

Carrouel, Florence, Gadea, Emilie, Esparcieux, Aurélie, Dimet, Jérome, Langlois, Marie Elodie, Perrier, Hervé, Dussart, Claude, and Bourgeois, Denis

Subjects
SARS-CoV-2, COVID-19, VIRAL load, ADULTS, AGE groups, SALIVA, VIRUS isolation, SALIVARY glands
Abstract

The fast spread of COVID-19 is related to the highly infectious nature of SARS-CoV-2. The disease is suggested to be transmitted through saliva droplets and nasal discharge. The saliva quantification of SARS-CoV-2 in real-time PCR from asymptomatic or mild COVID-19 adults has not been fully documented. This study analyzed the relationship between salivary viral load on demographics and clinical characteristics including symptoms, co-morbidities in 160 adults diagnosed as COVID-19 positive patients recruited between September and December 2020 in four French centers. Median initial viral load was 4.12 log10 copies/mL (IQR 2.95–5.16; range 0–10.19 log10 copies/mL). 68.6% of adults had no viral load detected. A median load reduction of 23% was observed between 0–2 days and 3–5 days, and of 11% between 3–5 days and 6–9 days for the delay from onset of symptoms to saliva sampling. No significant median difference between no-symptoms vs. symptoms patients was observed. Charge was consistently similar for the majority of the clinical symptoms excepted for headache with a median load value of 3.78 log10 copies/mL [1.95–4.58] (P < 0.003). SARS-CoV-2 RNA viral load was associated with headache and gastro-intestinal symptoms. The study found no statistically significant difference in viral loads between age groups, sex, or presence de co-morbidity. Our data suggest that oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients.

Author

Aparicio, Thomas, Henriques, Julie, Manfredi, Sylvain, Tougeron, David, Bouché, Olivier, Pezet, Denis, Piessen, Guillaume, Coriat, Romain, Zaanan, Aziz, Legoux, Jean‐Louis, Terrebone, Eric, Pocard, Marc, Gornet, Jean‐Marc, Lecomte, Thierry, Lombard‐Bohas, Catherine, Perrier, Hervé, Lecaille, Cédric, Lavau‐Denes, Sandrine, Vernerey, Dewi, and Afchain, Pauline

Subjects
HEREDITARY nonpolyposis colorectal cancer, ADENOMATOUS polyposis coli, CROHN'S disease, TUMOR classification, COHORT analysis
Abstract

Small bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence, survival and prognostic factors in unselected SBA patients. The study enrolled patients with all stages of newly diagnosed or recurrent SBA at 74 French centres between January 2009 and December 2012. In total, 347 patients were analysed; the median age was 63 years (range 23–90). The primary tumour was in the duodenum (60.6%), jejunum (20.7%) and ileum (18.7%). The prevalence of predisposing disease was 8.7%, 6.9%, 1.7%, 1.7% and 0.6% for Crohn disease, Lynch syndrome, familial adenomatous polyposis, celiac disease and Peutz‐Jeghers syndrome, respectively. At diagnosis, 58.9%, 5.5% and 35.6% of patients had localised and resectable, locally advanced unresectable and metastatic disease, respectively. Crohn disease was significantly associated with younger age, poor differentiation and ileum location, whereas Lynch syndrome with younger age, poor differentiation, early stage and duodenum location. Adjuvant chemotherapy (oxaliplatin‐based in 89.9%) was performed in 61.5% of patients with locally resected tumours. With a 54‐months median follow‐up, the 5‐year overall survival (OS) was 87.9%, 78.2% and 55.5% in Stages I, II and III, respectively. The median OS of patients with Stage IV was 12.7 months. In patients with resected tumours, poor differentiation (p = 0.047) and T4 stage (p = 0.001) were associated with a higher risk of death. In conclusion, our study showed that the prognosis of advanced SBA remains poor. Tumour characteristics differed according to predisposing disease. In SBA‐resected tumours, the prognostic factors for OS were grade and T stage. What's new? Small bowel adenocarcinoma is a rare disease but incidences are increasing in Europe and the US because of increases in duodenal cancers. This study from France found that Crohn's disease and Lynch syndrome, a genetic condition associated with colorectal cancers, combined with younger age and poor differentiation predisposed for the disease. The authors also linked poor differentiation and advanced tumor staging with short overall survival in patients with locally resected tumors, underscoring that the prognosis for advanced adenocarcinomas remains poor. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

21. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.

Author

Reichling, Cynthia, Taieb, Julien, Derangere, Valentin, Klopfenstein, Quentin, Le Malicot, Karine, Gornet, Jean-Marc, Becheur, Hakim, Fein, Francis, Cojocarasu, Oana, Kaminsky, Marie Christine, Lagasse, Jean Paul, Luet, Dominique, Nguyen, Suzanne, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Perrier, Hervé, Puig, Pierre-Laurent, Emile, Jean-François, and Lepage, Come

Subjects
COLON cancer, TISSUE analysis, CETUXIMAB
Published
2020
Full Text
View/download PDF

22. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Lang, Alois, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, Van Laethem, Jean-Luc, Van Cutsem, Eric, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, RezaieKalantari, Hassan, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Ychou, Marc, Zawadi, Ayman, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, MatysiakBudnik, Tamara, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, GuenterDerigs, Hans, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Labianca, Roberto, Colucci, Giuseppe, Amadori, Dino, Mini, Enrico, Falcone, Alfredo, Boni, Corrado, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Corsi, Domenico Cristi, Salvagni, Stefania, Chiara, Silvana, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Tabernero, Josep, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Valera, Javier Sastre, ValladaresAyerbes, Manuel, FeliuBatlle, Jaime, Gil, Silvia, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, CireraNogueras, Luis, Merino, BernadoQueralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, PijaumePericay, Carlos, ConstenlaFigueiras, Manuel, Jordan, InmaculadaGuasch, GomeReina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, MarcuelloGaspar, Eugenio, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, GuillotMorales, Monica, LlanosMuñoz, Marta, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, HernandezBusquier, Isabel, Ruiz, Teresa Checa, LacastaMuñoa, Adelaida, Aliguer, MiquelNogue, Ortiz de Taranco, Amalia Velasco, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, GalanBrotons, Antonio, AlbiolRodriguez, Santiago, Martinez, Jose Ales, Ruiz, Liliana Canosa, CentellesRuiz, Margarita, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, and Samuel, Leslie

Published
2015
Full Text
View/download PDF

27. Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2.

Author

Carrouel, Florence, Valette, Martine, Perrier, Hervé, Bouscambert-Duchamp, Maude, Dussart, Claude, Tramini, Paul, Bourgeois, Denis, Martinez-Sobrido, Luis, and Almazan Toral, Fernando

Subjects
SARS-CoV-2, SALIVA analysis, COVID-19, SALIVA, VIRAL load, ADULTS
Abstract

The aim of this study was to determine whether self-collected pure saliva (SCPS) is comparable to nasopharyngeal (NP) swabs in the quantitative detection of SARS-CoV-2 by RT-PCR in asymptomatic, mild patients with confirmed COVID-19. Thirty-one patients aged from 18 to 85 years were included between 9 June and 11 December 2020. A SCPS sample and a NP sample were taken for each patient. Quantitative PCR was performed to detect SARS-CoV-2 viral load. Results of SCPS vs. NP samples testing were compared. Statistical analyses were performed. Viral load was significantly correlated (r = 0.72). The concordance probability was estimated at 73.3%. In symptomatic adults, SCPS performance was similar to that of NP swabs (Percent Agreement = 74.1%; p = 0.11). Thus, the salivary test based on pure oral saliva samples easily obtained by noninvasive techniques has a fair agreement with the nasopharyngeal one in asymptomatic, mild patients with a confirmed diagnosis of COVID-19. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis.

Author

Adhoute X, Pietri O, Pénaranda G, Wolf T, Beaurain P, Monnet O, Laquière A, Bonomini J, Neumann F, Levrel O, Buono JP, Hanna X, Castellani P, Perrier H, Bourliere M, and Anty R

Abstract

Background and Aims: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) have common features and differences. This real-life study investigated their characteristics, treatment modalities, and prognoses., Methods: This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December 2020. Overall survival (OS) was estimated by the Kaplan-Meier method. Subclassification of iCCAs after histological and radiological review, and molecular profiling was performed., Results: HCCs patients were more likely to have early-stage disease than iCCA patients. iCCA patients were more likely to be female, especially those patients without cirrhosis (43% vs. 17%). Cirrhosis was prominent among HCC patients (89% vs. 34%), but no difference in underlying liver disease among cirrhotic patients was found. OS of HCC patients was 18.4 (95% CI: 6.4, 48.3) months, that of iCCA patients was 7.0 (95% CI: 3.4, 20.1) months. OS of Barcelona Clinic Liver Cancer C HCC patients was 7.8 (95% CI: 4.3, 14.2) months, that of advanced/metastatic iCCA patients was 8.5 (95% CI: 5.7, 12.3) months. In patients treated with sorafenib, OS was longer in HCC patients who received subsequent tyrosine kinase inhibitor therapies. No significant OS difference was found between iCCA patients with and without cirrhosis or according to histological subtype. A targetable molecular alteration was detected in 50% of the iCCA patients., Conclusions: In this French series, cirrhosis was common in iCCA, which showed etiological factors comparable to those of HCC, implying a distinct oncogenic pathway. Both entities had a dismal prognosis at advanced stages. However, systemic therapies sequencing in HCC and molecular profiling in iCCA offer new insights., Competing Interests: XA: Board member, Consultancy (Bayer, Ipsen, Eisai, Servier); PC: Consultancy (Gilead, Abbvie); MB: Board member, Consultancy (Merck-Schering Plow, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, GSK); HP: Consultancy (Sanofi); RA: Board member, Consultancy (Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen); OP: Abbvie, Gilead; AL: Boston Scientific. GP, JB, TW, PB, OM, FN, OL, JPB and XH have no conflict of interests related to this publication., (© 2023 Authors.)

Published
2023
Full Text
View/download PDF

30. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.

Author

Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, and Anty R

Abstract

Background: Starting a second-line systemic treatment for hepatocellular carcinoma (HCC) is a common situation. The only therapeutic options in France are two broad-spectrum tyrosine kinase inhibitors (TKIs), regorafenib (REG) and cabozantinib (CBZ), but no comparative real-life studies are available., Aim: To evaluate the progression-free survival (PFS) of patients treated with REG or CBZ, we investigated the disease control rate (DCR), overall survival (OS), and safety of both drugs. To identify the variables associated with disease progression over time., Methods: A retrospective multicenter study was performed on the clinical data of patients attending one of three referral centers (Avignon, Marseille, and Nice) between January 2017 and March 2021 using propensity score matching. PFS and OS were assessed using the Kaplan-Meier method. Multivariate analysis (MA) of progression risk factors over time was performed in matched-pair groups., Results: Fifty-eight patients 68 (62-74) years old with HCC, Barcelona clinic liver cancer (BCLC) B/C (86%), Child-Pugh (CP)-A/B (24%) received REG for 3.4 (1.4-10.5) mo as second-line therapy. Twenty-eight patients 68 (60-73) years, BCLC B/C (75%), CP-A/B (25%) received CBZ for 3.7 (1.8-4.9) mo after first-line treatment with sorafenib [3 (2-4) (CBZ) vs 4 (2.9-11.8) mo (REG), P = 0.0226]. Twenty percent of patients received third-line therapy. After matching, PFS and DCR were not significantly different after a median follow-up of 6.2 (2.7-11.7) mo (REG) vs 5.2 (4-7.2) mo (CBZ), P = 0.6925. There was no difference in grade 3/4 toxicities, dose reductions, or interruptions. The OS of CP-A patients was 8.3 (5.2-24.8) vs 4.9 (1.6-11.7) mo (CP-B), P = 0.0468. The MA of risk factors for progression over time identified C-reactive protein (CRP) > 10 mg/L, neutrophil-to-lymphocyte ratio (NLR) > 3, and aspartate aminotransferase (AST) > 45 IU as predictive factors., Conclusion: This multicenter indirect comparative study found no significant difference in PFS between REG and CBZ as second-line therapy for advanced HCC. Elevated levels of inflammatory markers (CRP and NLR) and AST were associated with non-control of TKIs over time. A 2-mo online progression risk calculation is proposed., Competing Interests: Conflict-of-interest statement: Xavier Adhoute: Board member, Consultancy (Bayer, Ipsen, Eisai, Servier); Laurent Mineur: Board member, Consultancy (Ipsen, Amgen, Travel, Mundipharma, Eisai); Clemence Toullec: Board member, Consultancy (Amgen, Bayer, BMS, Ipsen, Merck-Serono, MSD, Pierre-Fabre, Sanofi, Servier); Albert Tran: Board member, Consultancy (Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen); Valérie Oules: Consultancy (Gilead, Abbvie); Paul Castellani: Consultancy (Gilead, Abbvie); Marc Bourlière: Board member, Consultancy (Merck-Schering Plow, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, GSK); Si Nafa Si Ahmed: Consultancy (Gilead); Hervé Perrier: Consultancy (Sanofi); Rodolphe Anty: Board member, Consultancy (Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen); Guillaume Pénaranda, Armelle Rollet, Dann Ouizeman and Marie De Matharel have no conflicts of interest., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

31. Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

Author

Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, and Bourliere M

Abstract

Background: Careful selection of hepatocellular carcinoma (HCC) patients prior to chemoembolization treatment is a daily reality, and is even more necessary with new available therapeutic options in HCC., Aim: To propose two new models to better stratify patients and maximize clinical benefit: "6 and 12" and "pre/post-TACE-predict" (TACE, transarterial chemoembolization)., Methods: We evaluated and compared their performance in predicting overall survival with other systems {Barcelona Clinic Liver Cancer (BCLC), Albumin-Bilirubin (ALBI) and NIACE [Number of tumor(s), Infiltrative HCC, alpha-fetoprotein, Child-Pugh (CP), and performance status]} in two HCC French cohorts of different stages enrolled between 2010 and 2018., Results: The cohorts included 324 patients classified as BCLC stages A/B (cohort 1) and 137 patients classified as BCLC stages B/C (cohort 2). The majority of the patients had cirrhosis with preserved liver function. "Pre-TACE-predict" and "6 and 12" models identified three distinct categories of patients exhibiting different prognosis in cohort 1. However, their prognostic value was no better than the BCLC system or NIACE score. Liver function based on CP and ALBI grades significantly impacted patient survival. Conversely, the "post-TACE-predict" model had a higher predictive value than other models. The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient (cohort 2)., Conclusion: The newly proposed "Pre-TACE-predict" and "6 and 12" models offer an interesting stratification into three categories in a recommended TACE population, as they identify poor candidates, those with partial control and durable response. The models' contribution was reduced in a population with advanced stage HCCs., Competing Interests: Conflict-of-interest statement: The authors have no potential conflict of interest relative to this article. Adhoute X: Board member (Bayer, Ipsen, Eisai); Grant from Ipsen, Eisai. Anty R: Board member (Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen). Chevallier P: Board member (Bayer). Tran A: Board member (Gilead, Bayer, Eisai, Intercept, Abbvie, MSD, Ipsen). Bronowicki JP: Board member (Merck-Schering Plough, Janssen, Roche, BMS, Boehringer-Ingelheim, Gilead, Novartis, GSK, Bayer). Raoul JL: Board member (Bayer, BMS, Daichi). Castellani P: Board member (Gilead). Bourlière M: Board member (Merck-Schering Plough, Gilead, Janssen, Vertex, Boehringer-Ingelheim, BMS, Roche, Abbvie, GSK). Pénaranda G, Perrier H, Monnet O, Bayle O and Pol B have no conflict of interest., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

32. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.

Author

Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, and Bourlière M

Abstract

Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis., Methods: This was a retrospective study of advanced HCC patients treated with sorafenib between 2007 and 2017., Results: 188 advanced HCC patients received > 4 weeks of sorafenib. Median treatment duration was 5.4 months and median overall survival (mOS) 10 months (95% confidence interval 15-27). Sorafenib was initiated in 65 patients in 2007-2012 and 123 in 2013-2017. Both groups were comparable except for Barcelona Clinic liver cancer class. Tumor progression, disease control (DC) rate, and incidence of toxicity were similar in the 2 periods, but the duration of treatment (4.3 vs. 5.9 months; p < 0.01) and mOS (8 vs. 12 months; p < 0.002) differed. Among progressive disease patients, mOS was similar (7 months) but for those who had DC at 8 weeks, mOS was longer in the recent period (13 vs. 27 months; p < 0.0001). In the univariate analysis of OS, the period of treatment had a prognostic value., Conclusion: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC., Competing Interests: JLR is a Board member of Bayer, BMS, BTG, Terumo, and Astra-Zeneca. XA is a Board member of Bayer. GP grant from Bayer; MB is a Board member of Merck-Schering Plough, Janssen, Roche, Gilead, Novartis, and Bayer., (Copyright © 2019 by S. Karger AG, Basel.)

Published
2019
Full Text
View/download PDF

33. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Author

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, and Bourlière M

Subjects
Aged, Carcinoma, Hepatocellular mortality, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular therapy, Disease Progression, Disease-Free Survival, Female, France, Humans, Kaplan-Meier Estimate, Liver Neoplasms mortality, Liver Neoplasms pathology, Liver Neoplasms therapy, Male, Middle Aged, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Carcinoma, Hepatocellular diagnosis, Decision Support Techniques, Liver Neoplasms diagnosis, Neoplasm Staging methods, Nomograms
Abstract

Aim: To compare the performances of the Barcelona clinic liver cancer (BCLC) nomogram and others systems (BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma (HCC) French cohort., Methods: Data were collected retrospectively from 01/2007 to 12/2013 in five French centers. Newly diagnosed HCC patients were analyzed. The discriminatory ability, homogeneity ability, prognostic stratification ability Akaike information criterion (AIC) and C-index were compared among scoring systems., Results: The cohort included 1102 patients, mostly men, median age 68 [60-74] years with cirrhosis (81%), child-Pugh A (73%), alcohol-related (41%), HCV-related (27%). HCC were multinodular (59%) and vascular invasion was present in 41% of cases. At time of HCC diagnosis BCLC stages were A (17%), B (16%), C (60%) and D (7%). First line HCC treatment was curative in 23.5%, palliative in 59.5%, BSC in 17% of our population. Median OS was 10.8 mo [4.9-28.0]. Each system distinguished different survival prognosis groups ( P < 0.0001). The nomogram had the highest discriminatory ability, the highest C-index value. NIACE score had the lowest AIC value. The nomogram distinguished sixteen different prognosis groups. By classifying unifocal large HCC into tumor burden 1, the nomogram was less powerful., Conclusion: In this French cohort, the BCLC nomogram and the NIACE score provided the best prognostic information, but the NIACE could even help treatment strategies., Competing Interests: Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

Published
2017
Full Text
View/download PDF

34. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Author

Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, and Bourlière M

Abstract

Therapeutic management of hepatocellular carcinoma (HCC) is quite complex owing to the underlying cirrhosis and portal vein hypertension. Different scores or classification systems based on liver function and tumoral stages have been published in the recent years. If none of them is currently "universally" recognized, the Barcelona Clinic Liver Cancer (BCLC) staging system has become the reference classification system in Western countries. Based on a robust treatment algorithm associated with stage stratification, it relies on a high level of evidence. However, BCLC stage B and C HCC include a broad spectrum of tumors but are only matched with a single therapeutic option. Some experts have thus suggested to extend the indications for surgery or for transarterial chemoembolization. In clinical practice, many patients are already treated beyond the scope of recommendations. Additional alternative prognostic scores that could be applied to any therapeutic modality have been recently proposed. They could represent complementary tools to the BCLC staging system and improve the stratification of HCC patients enrolled in clinical trials, as illustrated by the NIACE score. Prospective studies are needed to compare these scores and refine their role in the decision making process.

Published
2016
Full Text
View/download PDF

35. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.

Author

Francois E, Smith D, Dahan L, Michel C, Perrier H, Mari V, Seitz JF, Follana P, Evesque L, and Chamorey E

Subjects
Adult, Aged, Aged, 80 and over, Anorexia chemically induced, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Asthenia chemically induced, Colorectal Neoplasms pathology, Drug Combinations, Drug Monitoring, Female, Humans, Leucovorin administration & dosage, Leucovorin adverse effects, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Male, Middle Aged, Mitomycin administration & dosage, Mitomycin adverse effects, Neoplasm Grading, Survival Analysis, Tegafur administration & dosage, Tegafur adverse effects, Tumor Burden drug effects, Uracil administration & dosage, Uracil adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Leucovorin therapeutic use, Mitomycin therapeutic use, Salvage Therapy adverse effects, Tegafur therapeutic use, Uracil therapeutic use
Abstract

We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC). This was a multicenter, prospective phase II study. Patients received MMC 7 mg/m² on day 1 and UFT 300 mg/m² with leucovorin 90 mg, both divided into three daily doses, on days 1-28 every 5 weeks. All patients had failed prior treatment with irinotecan, oxaliplatin, fluoropyrimidine, bevacizumab, and cetuximab. The primary endpoint was tumor control rate evaluated after 2 cycles. Twenty-one patients were included: median age was 66 years (41.1-87.8 years). Tumor control rate was observed in 26.7% of the 15 patients evaluable for response. Median overall survival was 6.4 months. Grade 3 adverse events were asthenia, anorexia, and vomiting. In patients with mCRC who have progressed after as many as two prior therapies, the combination of UFT/leucovorin and MMC is safe and may produce a short stabilization of disease in approximately 25% of patients.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results